Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia

Genes Chromosomes and Cancer

Volumn 54, Issue 11, 2015, Pages 668-680

  Salaverria, Itziar ^a   Martín Garcia, David ^a   López, Cristina ^a,b   Clot, Guillem ^a   García Aragonés, Manel ^c   Navarro, Alba ^a   Delgado, Julio ^a   Baumann, Tycho ^a   Pinyol, Magda ^d   Martin Guerrero, Idoia ^b,e   Carrió, Ana ^a   Costa, Dolors ^a   Queirós, Ana C ^a   Jayne, Sandrine ^f   Aymerich, Marta ^a   Villamor, Neus ^a   Colomer, Dolors ^a   González, Marcos ^g   López Guillermo, Armando ^a   Campo, Elías ^a   Dyer, Martin J S ^f   Siebert, Reiner ^b   Armengol, Lluís ^c   Beà, Sílvia ^a   more..

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF KIEL   (Germany)

^c R and D Center   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

ADULT; ARTICLE; CANCER DIAGNOSIS; CHROMOSOME; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 2P; CHROMOSOME 2Q; CHROMOSOME 3P; CHROMOSOME 6Q; CHROMOSOME 7Q; CHROMOSOME 8Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOTHRIPSIS; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER ALTERATION; COPY NUMBER VARIATION; CYTOGENETICS; DNA HYBRIDIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; ISOCHROMOSOME; ISOCHROMOSOME 17Q; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRISOMY 12; AGED; CLINICAL TRIAL; DNA MICROARRAY; GENE DOSAGE; GENETICS; HUMAN GENOME; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PROCEDURES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; FEMALE; GENE DOSAGE; GENOME, HUMAN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 84941204442     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22277     Document Type: Article

References (61)

1. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J, Taylor AM, Fegan C, Moss P, Stankovic T. 2005. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 106:3175-3182.
2. Balatti V, Bottoni A, Palamarchuk A, Alder H, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM. 2012. NOTCH1 mutations in CLL associated with trisomy 12. Blood 119:329-331.
3. Baliakas P, Iskas M, Gardiner A, Davis Z, Plevova K, Nguyen-Khac F, Malcikova J, Anagnostopoulos A, Glide S, Mould S, Stepanovska K, Brejcha M, Belessi C, Davi F, Pospisilova S, Athanasiadou A, Stamatopoulos K, Oscier D. 2014. Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data. Am J Hematol 89:249-255.
4. Bassaganyas L, Bea S, Escaramis G, Tornador C, Salaverria I, Zapata L, Drechsel O, Ferreira PG, Rodriguez-Santiago B, Tubio JM, Navarro A, Martin-Garcia D, Lopez C, Martinez-Trillos A, Lopez-Guillermo A, Gut M, Ossowski S, Lopez-Otin C, Campo E, Estivill X. 2013. Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Leukemia 27:2376-2379.
5. Braggio E, Kay NE Vanwier S, Tschumper RC, Smoley S, Eckel-Passow JE Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD Fonseca R. 2012. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse. Leukemia 26:1698-1701.
6. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal CP, Fernandes SM, Thompson C, Macconaill L, Wu CJ, Van de PY, Correll M, Regev A, Neuberg D, Freedman AS. 2012. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 18:3791-3802.
7. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C Futreal PA. 2010. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-1113.
8. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, Pettitt AR Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P. 2007. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239.
9. Chapiro E, Leporrier N, Radford-Weiss I, Bastard C, Mossafa H, Leroux D, Tigaud I, De BM, Terre C, Brizard F, Callet-Bauchu E, Struski S, Veronese L, Fert-Ferrer S, Taviaux S, Lesty C, Davi F, Merle-Beral H, Bernard OA, Sutton L, Raynaud SD, Nguyen-Khac F. 2010. Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leuk Res 34:63-68.
10. Delgado J, Salaverria I, Baumann T, Martinez-Trillos A, Lee E, Jimenez L, Navarro A, Royo C, Santacruz R, Lopez C, Payer AR, Colado E, Gonzalez M, Armengol L, Colomer D, Pinyol M, Villamor N, Aymerich M, Carrio A, Costa D, Clot G, Gine E, Lopez-Guillermo A, Campo E, Bea S. 2014. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica 99:e231-e234.
11. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, Kern W, Haferlach T, Haferlach C. 2009. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117-124.
12. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S. 1995. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589.
13. Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, Fischer K, Hunstein W, Lichter P. 1997. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89:2516-2522.
14. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916.
15. Edelmann J, Holzmann K, Miller F, Winkler D, Buhler A, Zenz T, Bullinger L, Kuhn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Dohner H. 2012. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120:4783-4784.
16. Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A. 2015. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: A phase 2, single-arm trial. Lancet Oncol 16:169-176.
17. Forconi F, Rinaldi A, Kwee I, Sozzi E, Raspadori D, Rancoita PM, Scandurra M, Rossi D, Deambrogi C, Capello D, Zucca E, Marconi D, Bomben R, Gattei V, Lauria F, Gaidano G, Bertoni F. 2008. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. Br J Haematol 143:532-536.
18. Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de JD, Eldering E, van Oers MH, Mellink CH, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS. 2008. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn 10:442-451.
19. Gunn SR, Hibbard MK, Ismail SH, Lowery-Nordberg M, Mellink CH, Bahler DW, Abruzzo LV, Enriquez EL, Gorre ME, Mohammed MS, Robetorye RS. 2009. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia. Leukemia 23:1011-1017.
20. Gunnarsson R, Isaksson A, Mansouri M, Goransson H, Jansson M, Cahill N, Rasmussen M, Staaf J, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Juliusson G, Rosenquist R. 2010. Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: A high-resolution genomic screening of newly diagnosed patients. Leukemia 24:211-215.
21. Gunnarsson R, Mansouri L, Isaksson A, Goransson H, Cahill N, Jansson M, Rasmussen M, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Geisler C, Juliusson G, Rosenquist R. 2011. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica 96:1161-1169.
22. Hagenkord JM, Monzon FA, Kash SF, Lilleberg S, Xie Q, Kant JA. 2010. Array-based karyotyping for prognostic assessment in chronic lymphocytic leukemia: Performance comparison of Affymetrix 10K2.0, 250K Nsp, and SNP6.0 arrays. J Mol Diagn 12:184-196.
23. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. 2008. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456.
24. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von GU, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jager U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Buhler A, Winkler D, Zenz T, Bottcher S, Ritgen M, Mendila M, Kneba M, Dohner H, Stilgenbauer S. 2010. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174.
25. Houldsworth J, Guttapalli A, Thodima V, Yan XJ, Mendiratta G, Zielonka T, Nanjangud G, Chen W, Patil S, Mato A, Brown JR, Rai K, Chiorazzi N, Chaganti RS. 2014. Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leuk Lymphoma 55:920-928.
26. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolas P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clement B, de AE, Degos F, Ferguson ML, Geary P, Hayes DN, Hudson TJ, Johns AL, Kasprzyk A, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van d V, Futreal PA, Aburatani H, Bayes M, Botwell DD, Campbell PJ, Estivill X, Gerhard DS, Grimmond SM, Gut I, Hirst M, Lopez-Otin C, Majumder P, Marra M, McPherson JD, Nakagawa H, Ning Z, Puente XS, Ruan Y, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigo R, Guo G, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li Q, Lopez-Bigas N, Luo R, Muthuswamy L, Ouellette BF, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stein LD, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu H, Zhao S, Zhou G, Stein LD, Guigo R, Hubbard TJ, Joly Y, Jones SM, Kasprzyk A, Lathrop M, Lopez-Bigas N, Ouellette BF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SO, Futreal PA, Gerhard DS, Gunter C, Guyer M, Hudson TJ, McPherson JD, Miller LJ, Ozenberger B, Shaw KM, Kasprzyk A, Stein LD, Zhang J, Haider SA, Wang J, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DR, Hasel KW, Joly Y, Kaan TS, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolas P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DD, Cloonan N, deFazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, McPherson JD, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu Y, Ji J, Zhang X, Chen F, Hu X, Zhou G, Yang Q, Tian G, Zhang L, Xing X, Li X, Zhu Z, Yu Y, Yu J, Yang H, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevard L, Prokhortchouk E, Banks RE, Uhlen M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Borresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thoms G, van d V, van't VL, Calvo F. 2010. International network of cancer genome projects. Nature 464:993-998.
27. Kay NE, Eckel-Passow JE, Braggio E, Vanwier S, Shanafelt TD, Van Dyke DL, Jelinek DF, Tschumper RC, Kipps T, Byrd JC, Fonseca R. 2010. Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. Cancer Genet Cytogenet 203:161-168.
28. Knight SJ, Yau C, Clifford R, Timbs AT, Sadighi AE, Dreau HM, Burns A, Ciria C, Oscier DG, Pettitt AR, Dutton S, Holmes CC, Taylor J, Cazier JB, Schuh A. 2012. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. Leukemia 26:1564-1575.
29. Kolquist KA, Schultz RA, Slovak ML, McDaniel LD, Brown TC, Tubbs RR, Cook JR, Theil KS, Cawich V, Valentin C, Minier S, Neill NJ, Byerly S, Morton SA, Sahoo T, Ballif BC, Shaffer LG. 2011. Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis. Mol Cytogenet 4:25.
30. Lopez C, Delgado J, Costa D, Villamor N, Navarro A, Cazorla M, Gomez C, Arias A, Munoz C, Cabezas S, Baumann T, Rozman M, Aymerich M, Colomer D, Pereira A, Cobo F, Lopez-Guillermo A, Campo E, Carrio A. 2013. Clonal evolution in chronic lymphocytic leukemia: Analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosomes Cancer 52:920-927.
31. Malek SN. 2013. The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene 32:2805-2817.
32. Mian M, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, Marasca R, Uhr M, Stussi G, Kwee I, Cavalli F, Gaidano G, Zucca E, Bertoni F. 2013. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. Ann Oncol 24:1378-1384.
33. Murga Penas EM, Kawadler H, Siebert R, Frank M, Ye H, Hinz K, Becher C, Hummel M, Barth TF, Bokemeyer C, Stein H, Trumper L, Moller P, Marynen P, Du MQ, Yang X, Hansmann ML, Dierlamm J. 2006. A novel fusion of the MALT1 gene and the microtubule-associated protein 4 (MAP4) gene occurs in diffuse large B-cell lymphoma. Genes Chromosomes Cancer 45:863-873.
34. Nagel I, Szczepanowski M, Martin-Subero JI, Harder L, Akasaka T, Ammerpohl O, Callet-Bauchu E, Gascoyne RD Gesk S, Horsman D, Klapper W, Majid A, Martinez-Climent JA, Stilgenbauer S, Tonnies H, Dyer MJ, Siebert R. 2010. Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood 116:1317-1320.
35. O'Malley DP, Giudice C, Chang AS, Chang D, Barry TS, Hibbard MK, Chen R, Chen ST. 2011. Comparison of array comparative genomic hybridization (aCGH) to FISH and cytogenetics in prognostic evaluation of chronic lymphocytic leukemia. Int J Lab Hematol 33:238-244.
36. Ouillette P, Collins R, Shakhan S, Li J, Peres E, Kujawski L, Talpaz M, Kaminski M, Li C, Shedden K, Malek SN. 2011. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood 118:3051-3061.
37. Patel A, Kang SH, Lennon PA, Li YF, Rao PN, Abruzzo L, Shaw C, Chinault AC, Cheung SW. 2008. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia. Am J Hematol 83:540-546.
38. Pfeifer D, Pantic M, Skatulla I, Rawluk J, Kreutz C, Martens UM, Fisch P, Timmer J, Veelken H. 2007. Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood 109:1202-1210.
39. Poncet D, Belleville A, t'kint de RC, Roborel de CA Ben SE, Merle-Beral H, Callet-Bauchu E, Salles G, Sabatier L, Delic J, Gilson E. 2008. Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B-chronic lymphocytic leukemia. Blood 111:2388-2391.
40. Pospisilova S, Gonzalez D, Malcikova J, Trbusek M, Rossi D, Kater AP, Cymbalista F, Eichhorst B, Hallek M, Dohner H, Hillmen P, van OM, Gribben J, Ghia P, Montserrat E, Stilgenbauer S, Zenz T. 2012. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 26:1458-1461.
41. Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Bea S, Pinyol M, Martinez-Trillos A, Lopez-Guerra M, Colomer D, Navarro A, Baumann T, Aymerich M, Rozman M, Delgado J, Gine E, Hernandez JM, Gonzalez-Diaz M, Puente DA, Velasco G, Freije JM, Tubio JM, Royo R, Gelpi JL, Orozco M, Pisano DG, Zamora J, Vazquez M, Valencia A, Himmelbauer H, Bayes M, Heath S, Gut M, Gut I, Estivill X, Lopez-Guillermo A, Puente XS, Campo E, Lopez OC. 2012. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 44:47-52.
42. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, Weischenfeldt J, Jager N, Remke M, Shih D, Northcott PA, Pfaff E, Tica J, Wang Q, Massimi L, Witt H, Bender S, Pleier S, Cin H, Hawkins C, Beck C, von DA, Hans V, Brors B, Eils R, Scheurlen W, Blake J, Benes V, Kulozik AE, Witt O, Martin D, Zhang C, Porat R, Merino DM, Wasserman J, Jabado N, Fontebasso A, Bullinger L, Rucker FG, Dohner K, Dohner H, Koster J, Molenaar JJ, Versteeg R, Kool M, Tabori U, Malkin D, Korshunov A, Taylor MD, Lichter P, Pfister SM, Korbel JO. 2012. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148:59-71.
43. Rinaldi A, Mian M, Kwee I, Rossi D, Deambrogi C, Mensah AA, Forconi F, Spina V, Cencini E, Drandi D, Ladetto M, Santachiara R, Marasca R, Gattei V, Cavalli F, Zucca E, Gaidano G, Bertoni F. 2011. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol 154:590-599.
44. Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. 2013. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: Where do we stand?. Leuk Lymph 54:2351-2364.
45. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del G, Fabbri I, Bruscaggin G, Spina A, Deambrogi V, Marinelli C, Fama M, Greco R, Daniele M, Forconi G, Gattei F, Bertoni V, Deaglio F, Pasqualucci S, Guarini L, la-Favera A, Foa R, Gaidano RG. 2012. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119:2854-2862.
46. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R, Rasi S, Monti S, Deambrogi C, De PL, Wang J, Gattei V, Guarini A, Foa R, Rabadan R, Gaidano G. 2014. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123:2139-2147.
47. Royo C, Navarro A, Clot G, Salaverria I, Gine E, Jares P, Colomer D, Wiestner A, Wilson WH, Vegliante MC, Fernandez V, Hartmann EM, Trim N, Erber WN, Swerdlow SH, Klapper W, Dyer MJ, Vargas-Pabon M, Ott G, Rosenwald A, Siebert R, Lopez-Guillermo A, Campo E, Bea S. 2012. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 26:1895-1898.
48. Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A, Song JY, Woroniecka R, Rymkiewicz G, Klapper W, Hartmann EM, Sujobert P, Wlodarska I, Ferry JA, Gaulard P, Ott G, Rosenwald A, Lopez-Guillermo A, Quintanilla-Martinez L, Harris NL, Jaffe ES, Siebert R, Campo E, Bea S. 2013. CCND2 rearrangements are the most frequent genetic events in cyclin D1(-) mantle cell lymphoma. Blood 121:1394-1402.
49. Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, Wierda WG, Keating MJ, Luthra R. 2009. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn 11:25-34.
50. Schultz RA, Delioukina M, Gaal K, Bedell V, Smith DD, Forman SJ, McDaniel LD, Ballif BC, Shaffer LG, Slovak ML. 2011. Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis. Mol Cytogenet 4:4.
51. Schwaenen C, Nessling M, Wessendorf S, Salvi T, Wrobel G, Radlwimmer B, Kestler HA, Haslinger C, Stilgenbauer S, Dohner H, Bentz M, Lichter P. 2004. Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA 101:1039-1044.
52. Shaffer LG, McGowan-Jordan J, Schmid M. 2013. ISCN 2013: An International System for Human Cytogenetic Nomenclature. Basel: Karger.
53. Shi M, Cipollini MJ, Crowley-Bish PA, Higgins AW, Yu H, Miron PM. 2013. Improved detection rate of cytogenetic abnormalities in chronic lymphocytic leukemia and other mature B-cell neoplasms with use of CpG-oligonucleotide DSP30 and interleukin 2 stimulation. Am J Clin Pathol 139:662-669.
54. Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, Dyer M, Matutes E, Gonzalez D, Taylor AM, Moss P, Thomas P, Oscier D, Stankovic T. 2012. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol 30:4524-4532.
55. Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, Sunter NJ, Mansouri L, Juliusson G, Smedby KE, Roos G, Jayne S, Majid A, Dearden C, Hall AG, Mainou-Fowler T, Jackson GH, Summerfield G, Harris RJ, Pettitt AR, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Catovsky D, Allan JM, Houlston RS. 2014. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet 46:56-60.
56. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC.
57. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S, Lopez C, Colomer D, Pinyol M, Aymerich M, Rozman M, Abrisqueta P, Baumann T, Delgado J, Gine E, Gonzalez-Diaz M, Hernandez JM, Colado E, Payer AR Rayon C, Navarro B, Jose TM, Bosch F, Quesada V, Puente XS, Lopez-Otin C, Jares P, Pereira A, Campo E, Lopez-Guillermo A. 2013. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 27:1100-1106.
58. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A, Denzel T, Winkler D, Edelmann J, Schwanen C, Dohner H, Stilgenbauer S. 2008. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: Results from a detailed genetic characterization with long-term follow-up. Blood 112:3322-3329.
59. Zenz T, Habe S, Denzel T, Mohr J, Winkler D, Buhler A, Sarno A, Groner S, Mertens D, Busch R, Hallek M, Dohner H, Stilgenbauer S. 2009. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589-2597.
60. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. 2010. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50.
61. Zenz T, Mertens D, Dohner H, Stilgenbauer S. 2011. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 25:131-137.